VEGFA rs833070: What Your Genotype Means

What each genotype means

Understanding the rs833070 Variant

The rs833070 variant is a specific change in the DNA sequence of the VEGFA gene, which is located on chromosome 6. In genetics, a single nucleotide polymorphism (SNP) like rs833070 represents a variation at a single position in the genome where different individuals may carry different building blocks, or alleles. For this specific variant, the two possible alleles are A and G. Because humans inherit two copies of every gene—one from each parent—an individual can have one of three possible genotype combinations: AA, AG, or GG. Scientists track these variations to understand if they correlate with differences in biological traits or, in the case of pharmacogenomics, how a person might respond to a specific medication. This variant is situated in a region of the gene that researchers hypothesize may affect the regulation or expression of the protein it encodes.

The Role of the VEGFA Gene

The VEGFA gene provides instructions for making a protein called vascular endothelial growth factor A. This protein plays a critical role in angiogenesis, the process of creating new blood vessels. Under normal conditions, VEGFA helps maintain healthy blood vessel growth and repair. However, in conditions like neovascular age-related macular degeneration (AMD), the body produces excessive amounts of this protein in the eye. This leads to the growth of abnormal, leaky blood vessels that can damage the retina and impair vision. Anti-VEGF therapies are medications designed to bind to and inhibit the activity of the VEGFA protein, effectively slowing or stopping the growth of these harmful vessels. Because the VEGFA gene is the target of these drugs, researchers investigate whether genetic variations within the gene itself might alter the protein's production or the drug's effectiveness in different patients.

Research and Evidence Strength

The evidence linking rs833070 to clinical outcomes is considered moderate and remains a subject of ongoing scientific inquiry. Some studies have explored whether specific genotypes at this location correlate with how well patients respond to anti-VEGF injections, such as ranibizumab or bevacizumab. While some early research suggested that certain alleles might predict a better visual outcome or a higher likelihood of responding to treatment, other large-scale clinical trials have yielded mixed or inconclusive results. It is important to recognize that complex conditions like macular degeneration are influenced by many factors, including age, environment, and a wide array of genetic markers. Consequently, no single SNP is currently used as a definitive tool to predict an individual's response to therapy. The scientific community continues to study these associations to determine if they can eventually help tailor treatment plans, but current evidence does not support using this variant for clinical decision-making.

Population Frequency

The rs833070 variant is relatively common in the general population. According to available genetic databases, the minor allele frequency is approximately 0.3522. This means that the variation is widely distributed across different ancestral groups, and it is not considered a rare mutation. Because it is a common variant, many people carry at least one copy of the G or A allele. Understanding that this is a common genetic feature helps researchers distinguish it from rare, high-impact mutations that might cause disease on their own. Instead, common variants like rs833070 are typically studied for their subtle, cumulative effects on health or drug response rather than as primary drivers of a condition.

What This Information Means for You

If you have received information about your rs833070 genotype, it is important to view it in the proper context. This variant is a subject of scientific research, not a diagnostic tool. It cannot predict with certainty whether you will respond to a specific medication, nor can it diagnose macular degeneration. Genetic associations are statistical observations made across large groups of people and do not necessarily apply to any single individual. If you are currently undergoing treatment for an eye condition or are concerned about your vision, you should rely on the expertise of your ophthalmologist or retina specialist. They are the only ones who can evaluate your clinical progress and determine the best course of action for your specific health needs. Always discuss any questions regarding your medication, dosing, or treatment response with your clinician or pharmacist, as they can provide guidance based on your full medical history.

Frequently asked questions

Sources & further reading

Related variants in VEGFA